Cusabio Technology LLC

As diabetes rates rise, GCGR (Glucagon Receptor) is gaining attention for its role in regulating blood glucose. Drugs targeting GCGR, developed by Novo Nordisk and Eli Lilly, are already on the market. The combination of GCGR with multi-target receptor agonists is emerging as a promising new approach. With more companies entering the space, the GCGR market is set for disruption. Today, let's learn more about GCGR. bit.ly/4iUkKoF

GCGR: A Regulator of Energy Balance Holds a Potential in Treatment Diabetes - Cusabio With the increase in the number of diagnosed diabetes, the diabetes drugs market is estimated to grow year by year. The new drugs design over diabetes treatment has soaked up more ink and excited more passion in recent years. GCGR, as a key molecule for regulating blood glucose l

A recent study reveals how Neurotensin (NTS) regulates food intake by controlling lipid metabolism in white adipocytes. Depleting NTSR2 in adipocytes increased food intake, while NTS treatment suppressed it. The mechanism involves ceramide synthetase 2, which increases ceramides C20–C24, raising food intake and lowering GDF15 levels. The study also found a correlation between ceramide levels and food intake across different populations. These findings highlight the role of NTS-NTSR2 signaling and ceramides in appetite regulation.

Learn more: https://www.nature.com/articles/s41422-024-01038-8